COVINA, Calif., Nov. 30 /PRNewswire/ -- StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells. This method and IP was pioneered by a team led by Professor John Lin, MD, PhD and members of Academia Sinica. Professor Lin is currently the exclusive collaborator with StemCyte on this indication and method.
"We are delighted to be working with Professor Lin and his team on this critical and broad medical indication," said Ken Giacin, StemCyte's CEO. "Stroke affects millions of people every year throughout the world and can be a debilitating disorder. Securing this agreement with Academia Sinica coupled with related IP that StemCyte owns will allow us to pursue the clinical and potential commercial application of Adult stem cells to treat this disorder."
According to the World Health Organization, chronic stroke is known to affect 15 million people worldwide annually. Professor Lin has been collaborating with StemCyte on this indication and potential method of treatment for 3 years. Through Professor Lin's pioneering efforts, he has completed a Phase Ib/IIa clinical trial and is currently completing the Phase II study. The pre-clinical as well as Phase I study has shown significant improvement in patients and preliminary indications from the Phase II study are also showing improvement. "We are extremely pleased with the improvement of the motor scores of the chronic stroke patients who received the therapy during our Phase I trial and I am confident that we will see similar results in the Phase II clinical trial," said Prof. John Lin, MD, PhD. "We are able to measure significant improvement after only 3 months based on both N.I.H. Stroke Scale and European Stroke scale. I am very confident that this treatment will become the method of choice to treat chronic stroke victims."
StemCyte has the most racially diverse collection of life-giving cell units derived from umbilical cord blood in the world and has successfully developed the leading such bank in Taiwan. With over 1,000 successful transplants using their units worldwide, StemCyte has focused on leveraging its proven publicly banked units to enhance regenerative bio-therapies for major indications affecting blood, nerve, brain and sensitive tissue cells. This exclusive agreement for the IP and commercial method to potentially treat chronic stroke is in addition to the other patent protected methods of optimal cell collection, storage and treatment.
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,000 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and supporting trials investigating regenerative spinal cord therapies. They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units. Its headquarters are located in Covina, Ca. and Ewing, NJ. To learn more visit www.StemCyte.com.
About Professor John Lin, MD PhD
Shinn-Zong Lin, M.D., Ph.D. (John Lin), Professor of Neurosurgery of China Medical University Hospital and Vice Superintendent, Center for Neuropsychiatry, is the principal investigator for the chronic stroke indication and methods of treatment under Academia Sinica in Taiwan. He is a distinguished expert in neuroscience and neurosurgery contributing to more than 150 reviewed papers, delivering over 150 presentations to specialists and receiving 25 honors around the globe since 1980. His research findings and publications have been referenced by experts in the field.
About Academia Sinica.. Academia Sinica was founded in 1928 to promote and undertake scholarly research in sciences and humanities. After the government moved to Taiwan in 1949, Academia Sinica was re-established in Taipei. Its mission is to promote the internal integration of research activities in three research disciplines; mathematics and physical sciences, life sciences, and humanities and social sciences. It is now a modern research institutions consisting of 24 research institutes and seven research centers headed by world-renowned scholars and staffed by highly trained, motivated, and creative young investigators.
SOURCE StemCyte, Inc.